Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objective Among Alzheimer disease (AD) patients enrolled in a clinical trial, the authors assessed the ability of a standardized capacity assessment procedure to identify persons who are capable of giving their own informed consent. Design Cross-sectional interview. Setting Thirteen sites participating in a randomized and placebo controlled study of simvastatin for the treatment of mild to moderate AD. Participants Persons with mild to moderate AD and their study partners enrolled in the simvastatin clinical trial. Measurements Interviews to assess decision-making capacity using the MacArthur Competency Assessment Tool for Clinical Research (MacCAT-CR). Results Judges blinded to the subject's clinical status had a high rate of agreement on patients capable of giving their own informed consent (kappa = 0.73). The understanding subscale had the best receiver operator characteristic and an analysis of positive and negative predictive values over a range of hypothetical prevalences of incapacity to consent demonstrated the value of a range of understanding cut-points. Conclusion Among mild to moderate AD patients, enrolled in an actual clinical trial, these results suggest evidence based guidelines for using the MacCAT-CR understanding subscale to help guide judgments about whether a patient has the capacity to consent.

What this study adds

Evidence grade: High

This is a cross-sectional study. This study looked at how well a standardized assessment tool helped identify which people with mild to moderate Alzheimer disease could give their own informed consent for a clinical trial. It is about research procedures and consent, not about treating, curing or preventing Alzheimer disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Karlawish, J., Kim, S. Y., Knopman, D., van Dyck, C. H., James, B. D., & Marson, D. (2008). Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. https://doi.org/10.1097/jgp.0b013e318172b406

Vancouver

Karlawish J, Kim SY, Knopman D, van Dyck CH, James BD, Marson D. Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2008. doi:10.1097/jgp.0b013e318172b406. PMID: 18556397.

BibTeX

@article{karlawish2008-18556397,
  author  = {Karlawish, J. and Kim, S. Y. and Knopman, D. and van Dyck, C. H. and James, B. D. and Marson, D.},
  title   = {{Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials}},
  journal = {The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry},
  year    = {2008},
  doi     = {10.1097/jgp.0b013e318172b406},
  pmid    = {18556397},
  url     = {https://doi.org/10.1097/jgp.0b013e318172b406}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study looked at how well a standardized assessment tool helped identify which people with mild to moderate Alzheimer disease could give their own informed consent for a clinical trial. It is about research procedures and consent, not about treating, curing or preventing Alzheimer disease.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 4 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 1 of 2; Times cited 4 of 7; Citations per year 1 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 49 of 100.49 of 100 points earned51 not earned

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry)
Journal's citation record 2 / 4 American Journal of Geriatric Psychiatry: journal h-index 178 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2008 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 1 / 2 Blinded or placebo-controlled (as stated in the record)
Times cited 4 / 7 Cited 45 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.2 citations a year over 20 year(s) since 2008
Impact for its field and year 3 / 6 Cited 4.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 1 / 4 Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Daniel C. Marson: h-index 78 (OpenAlex, whole career)
Institution's track record 2 / 3 Johns Hopkins University: institution h-index 2,306 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 8 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 18556397)
Free to read 0 / 2 Behind a paywall — scores zero
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Treatments from nearby years

Also in Treatments

201 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →